Targeted drug combo hopes to extend life in stomach cancer
NCT ID NCT06962137
First seen Dec 29, 2025 · Last updated Jun 19, 2026 · Updated 27 times
Summary
This study tests whether adding the targeted drug zolbetuximab to standard chemotherapy (paclitaxel and ramucirumab) can help people with advanced stomach cancer live longer. It includes 100 adults whose tumors have a specific protein called CLDN18.2. Participants receive the drug combination as a second treatment after first-line therapy has stopped working.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC CANCER ADENOCARCINOMA METASTATIC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
AZ Delta Roeselare
NOT_YET_RECRUITINGRoeselare, Belgium
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Cliniques Universitaires Saint-Luc Brussels
NOT_YET_RECRUITINGBrussels, Belgium
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
HUB
NOT_YET_RECRUITINGBrussels, Belgium
Contact Email: •••••@•••••
-
UZ Gent
NOT_YET_RECRUITINGGhent, Belgium
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
UZ Leuven
RECRUITINGLeuven, 3000, Belgium
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
UZA
NOT_YET_RECRUITINGAntwerp, Belgium
Contact Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Zolbetuximab (a targeted antibody) plus paclitaxel and ramucirumab (standard chemotherapy drugs)
What this could lead to
If it works, this could offer a more effective second-line treatment option for people with a specific type of stomach cancer that has a certain protein (CLDN18.2).
What could go wrong
This is a Phase II trial with only 100 participants, so results are preliminary. The added drug may not improve survival and could increase side effects like infusion reactions or fatigue.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.